The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively
Authors
Keywords
-
Journal
Cancer Medicine
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-06-24
DOI
10.1002/cam4.4052
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study
- (2020) David J. Straus et al. BLOOD
- Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
- (2020) David M. O'Malley et al. GYNECOLOGIC ONCOLOGY
- EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma
- (2020) Jonathan Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma
- (2020) Lauren Shea et al. Current Hematologic Malignancy Reports
- Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer
- (2020) Emanuele Perrone et al. Frontiers in Oncology
- HER2-positive Advanced Breast Cancer Treatment in 2020
- (2020) Marcelle G Cesca et al. CANCER TREATMENT REVIEWS
- FDA Approval Summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer
- (2020) Suparna Wedam et al. CLINICAL CANCER RESEARCH
- Trastuzumab Deruxtecan: First Approval
- (2020) Susan J. Keam DRUGS
- Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas
- (2020) Jakub Svoboda et al. HAEMATOLOGICA
- Evolution of the Systems PK-PD Model for Antibody-drug Conjugates (ADC) to Characterize Tumor Heterogeneity and In Vivo Bystander Effect
- (2020) Aman P Singh et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Platinum-triggered Bond-cleavage of Pentynoyl amide and N-propargyl handles for Drug-Activation
- (2020) Bruno L. Oliveira et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer
- (2020) Kohei Shitara et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beyond the limitation of targeted therapy: Improve the application of targeted drugs combining genomic data with machine learning
- (2020) Rui Miao et al. PHARMACOLOGICAL RESEARCH
- Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
- (2020) Junji Tsurutani et al. Cancer Discovery
- HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers
- (2020) Bob T. Li et al. Cancer Discovery
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
- (2020) F. Montemurro et al. ANNALS OF ONCOLOGY
- Sacituzumab Govitecan: First Approval
- (2020) Yahiya Y. Syed DRUGS
- Trastuzumab-deruxtecan: an investigational agent for the treatment of HER2-positive breast cancer
- (2020) Rupert Bartsch EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Brentuximab vedotin and its use in the treatment of advanced Hodgkin’s lymphoma
- (2020) Liana Nikolaenko et al. Future Oncology
- Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer
- (2020) Kathleen N. Moore et al. GYNECOLOGIC ONCOLOGY
- Rituximab-CHOP With Early Rituximab Intensification for Diffuse Large B-Cell Lymphoma: A Randomized Phase III Trial of the HOVON and the Nordic Lymphoma Group (HOVON-84)
- (2020) Pieternella Johanna Lugtenburg et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolving therapy of adult acute lymphoblastic leukemia: state-of-the-art treatment and future directions
- (2020) Bachar Samra et al. Journal of Hematology & Oncology
- Personalized early detection and prevention of breast cancer: ENVISION consensus statement
- (2020) Nora Pashayan et al. Nature Reviews Clinical Oncology
- Synthesis of site-specific antibody-drug conjugates by ADP-ribosyl cyclases
- (2020) Zhefu Dai et al. Science Advances
- A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535)
- (2020) Jeffrey E. Lancet et al. Blood Advances
- 836P Safety and efficacy of XMT-1536 in ovarian cancer: A subgroup analysis from the phase I expansion study of XMT-1536, a NaPi2b antibody-drug conjugate
- (2020) E.P. Hamilton et al. ANNALS OF ONCOLOGY
- Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial
- (2020) K. Kalinsky et al. ANNALS OF ONCOLOGY
- Breaking Barriers in HER2+ Cancers
- (2020) Salvatore Siena et al. CANCER CELL
- Belantamab Mafodotin: First Approval
- (2020) Anthony Markham DRUGS
- BCMA-targeted immunotherapy for multiple myeloma
- (2020) Bo Yu et al. Journal of Hematology & Oncology
- Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
- (2020) Amy Burd et al. NATURE MEDICINE
- Development and biological assessment of MMAE-trastuzumab antibody–drug conjugates (ADCs)
- (2020) Sajad Yaghoubi et al. Breast Cancer
- Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
- (2020) Timothy J Voorhees et al. Cancers
- Brentuximab Vedotin and ESHAP is Highly Effective as Second-Line Therapy for Hodgkin Lymphoma Patients (Long-Term Results of a Trial by the Spanish GELTAMO Group)
- (2019) R Garcia-Sanz et al. ANNALS OF ONCOLOGY
- FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma
- (2019) Nicholas C. Richardson et al. ONCOLOGIST
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-Drug Conjugate-Based Therapeutics: State of the Science
- (2019) Michael J Birrer et al. JNCI-Journal of the National Cancer Institute
- Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
- (2019) Scott T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- Cardiovascular mortality among patients with non‐Hodgkin lymphoma: differences according to lymphoma subtype
- (2019) Hasan Abuamsha et al. HEMATOLOGICAL ONCOLOGY
- Biomarker analysis of the GATSBY study of trastuzumab emtansine versus a taxane in previously treated HER2-positive advanced gastric/gastroesophageal junction cancer
- (2019) Manish A. Shah et al. Gastric Cancer
- Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long‐term survival follow‐up from the randomized, phase 3 INO‐VATE study
- (2019) Hagop M. Kantarjian et al. CANCER
- The Role of Organic Synthesis in the Emergence and Development of Antibody-Drug Conjugates as Targeted Cancer Therapies
- (2019) Kyriacos C. Nicolaou et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
- (2019) Hervé Tilly et al. LANCET ONCOLOGY
- A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy
- (2019) John Y. Li et al. CANCER CELL
- Polatuzumab Vedotin: First Global Approval
- (2019) Emma D. Deeks DRUGS
- Potential drugs used in the antibody-drug conjugate (ADC) architecture for cancer therapy
- (2019) Sajad Yaghoubi et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study
- (2019) Sara A. Hurvitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
- (2019) Jonathan E. Rosenberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Considerations for the Design of Antibody-Based Therapeutics
- (2019) Dennis R. Goulet et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Fractionated gemtuzumab ozogamicin in association with high dose chemotherapy: a bridge to allogeneic stem cell transplantation in refractory and relapsed acute myeloid leukemia
- (2019) Pierre-Edouard Debureaux et al. BONE MARROW TRANSPLANTATION
- Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study
- (2019) Pier Luigi Zinzani et al. JOURNAL OF CLINICAL ONCOLOGY
- Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
- (2019) Bo Yu et al. Journal of Hematology & Oncology
- Antibody–drug conjugates for cancer
- (2019) Cindy H Chau et al. LANCET
- CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
- (2019) C. Kimberly Tsui et al. Nature Chemical Biology
- Brentuximab vedotin in the treatment of CD30-positive PTCL
- (2019) Stefan K. Barta et al. BLOOD
- The evolving role of trastuzumab emtansine (T-DM1) in HER2-positive breast cancer with brain metastases
- (2019) Rongrong Dong et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10
- (2019) Jame Abraham et al. JOURNAL OF CLINICAL ONCOLOGY
- Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- (2019) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Copper-Triggered Bioorthogonal Cleavage Reactions for Reversible Protein and Cell Surface Modifications
- (2019) Xin Wang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- Computationally designed antibody–drug conjugates self-assembled via affinity ligands
- (2019) Nimish Gupta et al. Nature Biomedical Engineering
- Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma
- (2019) Kirollos S. Hanna DRUGS
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial
- (2018) Anna Candoni et al. AMERICAN JOURNAL OF HEMATOLOGY
- Antibody–Drug Conjugates for Cancer Treatment
- (2018) John M. Lambert et al. Annual Review of Medicine
- Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma
- (2018) Ann S. LaCasce et al. BLOOD
- FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia
- (2018) Emily Y. Jen et al. CLINICAL CANCER RESEARCH
- A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia
- (2018) Bruno C. Medeiros et al. Clinical Lymphoma Myeloma & Leukemia
- The Chemical Design and Synthesis of Linkers Used in Antibody Drug Conjugates
- (2018) Mark Frigerio et al. CURRENT TOPICS IN MEDICINAL CHEMISTRY
- Tumor stroma–targeted antibody-drug conjugate triggers localized anticancer drug release
- (2018) Christopher Szot et al. JOURNAL OF CLINICAL INVESTIGATION
- Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial
- (2018) Bob T. Li et al. JOURNAL OF CLINICAL ONCOLOGY
- Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
- (2018) Hagop Kantarjian et al. LANCET ONCOLOGY
- Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial
- (2018) Sara A Hurvitz et al. LANCET ONCOLOGY
- Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma
- (2018) Joseph M. Connors et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33‐Positive Acute Myeloid Leukemia
- (2018) Kelly J. Norsworthy et al. ONCOLOGIST
- A developed antibody–drug conjugate rituximab-vcMMAE shows a potent cytotoxic activity against CD20-positive cell line
- (2018) Meghdad Abdollahpour-Alitappeh et al. Artificial Cells Nanomedicine and Biotechnology
- Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia
- (2018) Elias Jabbour et al. JAMA Oncology
- Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse
- (2018) Craig H. Moskowitz et al. BLOOD
- Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial
- (2018) Juliette Lambert et al. HAEMATOLOGICA
- Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
- (2018) Ilana R Yurkiewicz et al. Drug Design Development and Therapy
- Total Synthesis in Search of Potent Antibody–Drug Conjugate Payloads. From the Fundamentals to the Translational
- (2018) Kyriacos C. Nicolaou et al. ACCOUNTS OF CHEMICAL RESEARCH
- Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvage
- (2018) Elias Jabbour et al. CANCER
- Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
- (2018) Meghdad Abdollahpour-Alitappeh et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
- (2018) Steven Horwitz et al. LANCET
- Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition
- (2018) Haihong Zhong et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies
- (2018) Hao Xie et al. Journal of Thoracic Oncology
- Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment
- (2018) Chunlin Zhuang et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan
- (2017) Rebecca Suk Heist et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
- (2017) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
- (2017) H Miles Prince et al. LANCET
- Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study
- (2017) Peter C Thuss-Patience et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
- (2017) Kenneth M. Felsenstein et al. Nature Reviews Urology
- Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
- (2017) Hagop M Kantarjian et al. Lancet Haematology
- Combining antibody–drug conjugates and immune-mediated cancer therapy: What to expect?
- (2016) Hans-Peter Gerber et al. BIOCHEMICAL PHARMACOLOGY
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- (2016) R. Chen et al. BLOOD
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma
- (2016) M. Ogura et al. CLINICAL CANCER RESEARCH
- Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
- (2016) M.-L. Hutter-Kronke et al. HAEMATOLOGICA
- Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial
- (2016) A. Burnett et al. HAEMATOLOGICA
- Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial
- (2016) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
- (2016) Hagop M. Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody-drug conjugates: Current status and future perspectives
- (2016) Rémy Gébleux et al. PHARMACOLOGY & THERAPEUTICS
- Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions
- (2016) Tilman Schlothauer et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Antibody-drug conjugates: recent advances in conjugation and linker chemistries
- (2016) Kyoji Tsuchikama et al. Protein & Cell
- Salvage therapy with high-dose cytarabine and mitoxantrone in combination with all-trans retinoic acid and gemtuzumab ozogamicin in acute myeloid leukemia refractory to first induction therapy
- (2016) M.-L. Hutter-Kronke et al. HAEMATOLOGICA
- Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial
- (2016) A. Burnett et al. HAEMATOLOGICA
- Antibody Drug Conjugates: Design and Selection of Linker, Payload and Conjugation Chemistry
- (2015) Jessica R. McCombs et al. AAPS Journal
- Conformational Difference in Human IgG2 Disulfide Isoforms Revealed by Hydrogen/Deuterium Exchange Mass Spectrometry
- (2015) Aming Zhang et al. BIOCHEMISTRY
- Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma
- (2015) Robert Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Antibody-drug conjugates as novel anti-cancer chemotherapeutics
- (2015) C. Peters et al. BIOSCIENCE REPORTS
- Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression
- (2015) E. D. Jacobsen et al. BLOOD
- First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
- (2015) A. N. Starodub et al. CLINICAL CANCER RESEARCH
- Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
- (2015) Giulio Casi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome
- (2015) N Daver et al. LEUKEMIA
- Gemtuzumab ozogamicin in combination with intensive chemotherapy in relapsed or refractory acute myeloid leukemia
- (2015) Sylvain P. Chantepie et al. LEUKEMIA & LYMPHOMA
- Mechanisms of action of therapeutic antibodies for cancer
- (2015) J.M. Redman et al. MOLECULAR IMMUNOLOGY
- Evolving Strategies for Target Selection for Antibody-Drug Conjugates
- (2015) Marc Damelin et al. PHARMACEUTICAL RESEARCH
- Current ADC Linker Chemistry
- (2015) Nareshkumar Jain et al. PHARMACEUTICAL RESEARCH
- The biological complexity of urothelial carcinoma: Insights into carcinogenesis, targets and biomarkers of response to therapeutic approaches
- (2015) Petros D. Grivas et al. SEMINARS IN CANCER BIOLOGY
- Development and Integration of Antibody–Drug Conjugate in Non-Hodgkin Lymphoma
- (2015) Amitkumar Mehta et al. Current Oncology Reports
- Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy
- (2014) Ravi V. J. Chari et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation
- (2014) Maya Koren-Michowitz et al. ANNALS OF HEMATOLOGY
- Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
- (2014) I. E. Krop et al. ANNALS OF ONCOLOGY
- Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma
- (2014) Y.-T. Tai et al. BLOOD
- Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
- (2014) S. M. Horwitz et al. BLOOD
- FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer
- (2014) L. Amiri-Kordestani et al. CLINICAL CANCER RESEARCH
- Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
- (2014) John M. Lambert et al. JOURNAL OF MEDICINAL CHEMISTRY
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
- (2014) Robert K Hills et al. LANCET ONCOLOGY
- Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates
- (2014) Dowdy Jackson et al. PHARMACEUTICAL RESEARCH
- IgG Subclasses and Allotypes: From Structure to Effector Functions
- (2014) Gestur Vidarsson et al. Frontiers in Immunology
- A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
- (2013) S. H. Petersdorf et al. BLOOD
- Gemtuzumab ozogamicin in combination with vorinostat and azacitidine in older patients with relapsed or refractory acute myeloid leukemia: a phase I/II study
- (2013) R. B. Walter et al. HAEMATOLOGICA
- Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab
- (2013) Luis Fayad et al. JOURNAL OF CLINICAL ONCOLOGY
- Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17)
- (2013) Sergio Amadori et al. JOURNAL OF CLINICAL ONCOLOGY
- Novel agents and biomarkers for acute lymphoid leukemia
- (2013) Yanmin Zhao et al. Journal of Hematology & Oncology
- U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
- (2012) R. A. de Claro et al. CLINICAL CANCER RESEARCH
- Catabolic Fate and Pharmacokinetic Characterization of Trastuzumab Emtansine (T-DM1): an Emphasis on Preclinical and Clinical Catabolism
- (2012) Ben-Quan Shen et al. CURRENT DRUG METABOLISM
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
- (2012) Sylvie Castaigne et al. LANCET
- DNA Damage Repair Pathways in Cancer Stem Cells
- (2012) M. Maugeri-Sacca et al. MOLECULAR CANCER THERAPEUTICS
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats
- (2011) C. Andrew Boswell et al. BIOCONJUGATE CHEMISTRY
- Antibody Conjugate Therapeutics: Challenges and Potential
- (2011) B. A. Teicher et al. CLINICAL CANCER RESEARCH
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- Microtubule-binding agents: a dynamic field of cancer therapeutics
- (2010) Charles Dumontet et al. NATURE REVIEWS DRUG DISCOVERY
- Engineered anti-CD70 antibody-drug conjugate with increased therapeutic index
- (2008) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- (2008) Jagath R Junutula et al. NATURE BIOTECHNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now